BACKGROUND: Patients receiving 5-aminosalicylic acid (5-ASA) require long-term therapy to achieve good outcomes. Persistency (duration of time from initiation to discontinuation of therapy) is therefore an important consideration. AIM: To evaluate persistency in patients receiving various oral 5-ASA formulations. METHODS: This retrospective, 12-month, cohort study examined new-starter patients (any age and diagnosis) from a large United States pharmacy database who filled a prescription for oral 5-ASA [Lialda(®), Asacol(®), Pentasa(®) 250 or 500 mg, balsalazide (generic and Colazal(®)), and olsalazine (Dipentum(®))] between March and September 2007. Persistency was evaluated monthly on the basis of prescription refill rates. RESULTS: Prescription and refill records were identified for 44,191 patients receiving oral 5-ASA. After 1 year, 20% of patients receiving Lialda were considered persistent and classified as continuing (refilling within a timeframe of up to twice the duration of the prescription), compared with 9% receiving Asacol, 7 (250 mg) and 10% (500 mg) receiving Pentasa, 10% receiving balsalazide, and 10% receiving Dipentum. CONCLUSIONS: Overall persistency with oral 5-ASA therapy was low. However, patients receiving once-daily Lialda had significantly higher persistency after 1 year of treatment than patients receiving other oral 5-ASA therapies.
BACKGROUND:Patients receiving 5-aminosalicylic acid (5-ASA) require long-term therapy to achieve good outcomes. Persistency (duration of time from initiation to discontinuation of therapy) is therefore an important consideration. AIM: To evaluate persistency in patients receiving various oral 5-ASA formulations. METHODS: This retrospective, 12-month, cohort study examined new-starter patients (any age and diagnosis) from a large United States pharmacy database who filled a prescription for oral 5-ASA [Lialda(®), Asacol(®), Pentasa(®) 250 or 500 mg, balsalazide (generic and Colazal(®)), and olsalazine (Dipentum(®))] between March and September 2007. Persistency was evaluated monthly on the basis of prescription refill rates. RESULTS: Prescription and refill records were identified for 44,191 patients receiving oral 5-ASA. After 1 year, 20% of patients receiving Lialda were considered persistent and classified as continuing (refilling within a timeframe of up to twice the duration of the prescription), compared with 9% receiving Asacol, 7 (250 mg) and 10% (500 mg) receiving Pentasa, 10% receiving balsalazide, and 10% receiving Dipentum. CONCLUSIONS: Overall persistency with oral 5-ASA therapy was low. However, patients receiving once-daily Lialda had significantly higher persistency after 1 year of treatment than patients receiving other oral 5-ASA therapies.
Authors: Lisa J Herrinton; Liyan Liu; Bruce Fireman; James D Lewis; James E Allison; Nicole Flowers; Susan Hutfless; Fernando S Velayos; Oren Abramson; Andrea Altschuler; Geraldine S Perry Journal: Gastroenterology Date: 2009-05-13 Impact factor: 22.682
Authors: R D'Incà; P Bertomoro; K Mazzocco; M G Vettorato; R Rumiati; G C Sturniolo Journal: Aliment Pharmacol Ther Date: 2007-10-20 Impact factor: 8.171
Authors: David T Rubin; Corey A Siegel; Sunanda V Kane; David G Binion; Remo Panaccione; Marla C Dubinsky; Edward V Loftus; Joseph Hopper Journal: Inflamm Bowel Dis Date: 2009-04 Impact factor: 5.325
Authors: Leo Russo; Gary Schneider; Margarita Hauser Gardiner; Stephan Lanes; Paul Streck; Susan Rosen Journal: Eur J Clin Pharmacol Date: 2014-03-11 Impact factor: 2.953